Why Choose Shani Biotech?

We own a proprietary novel technology platform with the ability to non-invasively measure several blood parameters. Our technology does not require any invasive procedure (intradermal needle, skin patch) or blood draws/finger pricks. We are interested in measuring these parameters in subject’s blood, in contrast to some competitors with a focus on sweat, saliva or tears. We believe that the surrogate values in these body fluids (other than blood) have no known clinical utility.

The technology and the device are non-invasive, portable, with potential embodiment in wearables.

Our lead asset (SH-1) has undergone an extensive pre-clinical evaluation with promising results.  We anticipate the readout of a phase 1 study involving 16 adult participants sometime during Q3 2021. After appropriate regulatory feedback, we plan to begin a larger phase 2/phase 3 study in patients from Q4 2021.

Our second asset (SH-2) is currently in pre-clinical development and we envision a phase 1 study sometime in 2022.

The ultimate vision is to develop a wearable device with the ability to monitor several clinically relevant blood parameters.